By Topic

How Much Higher Can Recce Pharmaceuticals' (ASX: RCE) Share Price Go After the Recent Breakout?

Dec 8, 2025

Proactive Equities Team

Recce has recently attracted attention because it’s advancing drug candidates against serious infections, a space with significant potential if late-stage trials succeed. That kind of promise is why some market watchers see upside in RCE’s shares. On the flip side, the company remains unprofitable, with no consistent earnings or predictable cash flow, so it’s still a speculative biotech rather than a stable performer.

How Much Higher Can CETTIRE's (ASX: CTT) Share Price Go After the Recent Breakout?

Dec 8, 2025

Proactive Equities Team

Cettire (ASX: CTT) share price recently had a breakout. But it is in a bit of limbo; enough promise remains that a rebound could be on the cards, but enough uncertainty that it’s far from a safe bet. On one hand, the company is forecast to post healthy earnings-per-share growth over the next few years and has a pretty low price-to-sales ratio compared with peers, suggesting some latent value. On the other hand, consensus analyst targets hover modestly, some even see a drop, and many believe any upside beyond roughly one Australian dollar a share depends on improvements that aren’t guaranteed.

Macroeconomic Report for the Week Ending 5 December 2025 – Australian Market Outlook

Dec 8, 2025

Proactive Equities Team

Global data point to a softening but still mixed growth backdrop, with US manufacturing in mild contraction contrasted against resilient services activity. Labour indicators such as ADP employment and continuing jobless claims show cooling private hiring and more challenging re‑employment conditions, reinforcing expectations of earlier and deeper Federal Reserve rate cuts. Core US PCE inflation is running at a steady, moderate pace, allowing the Fed to stay on hold while waiting for clearer evidence that inflation is durably converging to the target.

Control Bionics (ASX: CBL) - This microcap's share price could explode higher from here!

Dec 4, 2025

Proactive Equities Team

The small-cap medical-tech company, Control Bionics, has just taken steps that could catapult it far beyond its current size. Its core product, a wearable sensor that translates even the faintest muscle or nerve signals into computer commands, is already approved and helps people with severe physical disabilities communicate and interact. Recently, the company announced that it had integrated a significant tech giant’s brain-computer interface protocol into its devices.

Investigator Silver (ASX: IVR)- Positions for Catalysts Amid Strengthening Silver Market

Dec 4, 2025

Proactive Equities Team

Investigator Silver (ASX: IVR), formerly known as Investigator Resources, is moving through one of the most strategically important phases in its history. The company is advancing the Paris Silver Project, Australia’s highest-grade undeveloped primary silver deposit, while simultaneously delivering exploration wins across its 100%-owned Peterlumbo tenement and progressing copper-gold targets at Uno Morgans.

NRW Holdings (ASX: NWH)-Positioned for Growth in FY26 and Beyond

Dec 4, 2025

Proactive Equities Team

NRW Holdings is emerging from FY25 with strengthened financial performance, record order book visibility, and renewed momentum across its mining, civil, and MET (Maintenance & Engineering) segments. With EBITDA growing, margins stabilising, and a robust pipeline supported by long-life Tier-1 resources projects, NWH has entered FY26 well-positioned for continued earnings expansion. The company’s durability across cycles, combined with strong cash generation and rising recurring revenue streams, reinforces the investment case for long-term holders.

...